| |  Online-Ressource |
|---|
| Verfasst von: | Jaramillo Segura, Sonia [VerfasserIn]  |
|---|
| | Krisam, Johannes [VerfasserIn] |
|---|
| | Le Cornet, Lucian [VerfasserIn] |
|---|
| | Kratzmann, Markus [VerfasserIn] |
|---|
| | Baumann, Lukas [VerfasserIn] |
|---|
| | Sauer, Tim [VerfasserIn] |
|---|
| | Crysandt, Martina [VerfasserIn] |
|---|
| | Rank, Andreas [VerfasserIn] |
|---|
| | Behringer, Dirk [VerfasserIn] |
|---|
| | Teichmann, Lino [VerfasserIn] |
|---|
| | Görner, Martin [VerfasserIn] |
|---|
| | Trappe, Ralf-Ulrich [VerfasserIn] |
|---|
| | Röllig, Christoph [VerfasserIn] |
|---|
| | Krause, Stefan [VerfasserIn] |
|---|
| | Hanoun, Maher [VerfasserIn] |
|---|
| | Hopfer, Olaf [VerfasserIn] |
|---|
| | Held, Gerhard [VerfasserIn] |
|---|
| | Buske, Sebastian [VerfasserIn] |
|---|
| | Fransecky, Lars [VerfasserIn] |
|---|
| | Kayser, Sabine [VerfasserIn] |
|---|
| | Schliemann, Christoph [VerfasserIn] |
|---|
| | Schaefer-Eckart, Kerstin [VerfasserIn] |
|---|
| | Al-Fareh, Yousef [VerfasserIn] |
|---|
| | Schubert, Jörg [VerfasserIn] |
|---|
| | Geer, Thomas [VerfasserIn] |
|---|
| | Kaufmann, Martin [VerfasserIn] |
|---|
| | Brecht, Arne [VerfasserIn] |
|---|
| | Niemann, Dirk [VerfasserIn] |
|---|
| | Kieser, Meinhard [VerfasserIn] |
|---|
| | Bornhäuser, Martin [VerfasserIn] |
|---|
| | Platzbecker, Uwe [VerfasserIn] |
|---|
| | Serve, Hubert [VerfasserIn] |
|---|
| | Baldus, Claudia D. [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Schlenk, Richard Friedrich [VerfasserIn] |
|---|
| Titel: | Rationale and design of the 2 by 2 factorial design GnG-trial |
|---|
| Titelzusatz: | a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML |
|---|
| Verf.angabe: | Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, Martina Crysandt, Andreas Rank, Dirk Behringer, Lino Teichmann, Martin Görner, Ralf-Ulrich Trappe, Christoph Röllig, Stefan Krause, Maher Hanoun, Olaf Hopfer, Gerhard Held, Sebastian Buske, Lars Fransecky, Sabine Kayser, Christoph Schliemann, Kerstin Schaefer-Eckart, Yousef Al-Fareh, Jörg Schubert, Thomas Geer, Martin Kaufmann, Arne Brecht, Dirk Niemann, Meinhard Kieser, Martin Bornhäuser, Uwe Platzbecker, Hubert Serve, Claudia D. Baldus, Carsten Müller-Tidow and Richard F. Schlenk |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | 03 November 2021 |
|---|
| Umfang: | 13 S. |
|---|
| Fussnoten: | Gesehen am 16.12.2021 |
|---|
| Titel Quelle: | Enthalten in: Trials |
|---|
| Ort Quelle: | London : BioMed Central, 2000 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 22(2021), Artikel-ID 765, Seite 1-13 |
|---|
| ISSN Quelle: | 1468-6694 |
|---|
| | 1745-6215 |
|---|
| Abstract: | Overall survival remains poor in older patients with acute myeloid leukemia (AML) with less than 10% being alive after 5 years. In recent studies, a significant improvement in event-free, relapse-free and overall survival was shown by adding gemtuzumab ozogamicin (GO), a humanized antibody-drug conjugate directed against CD33, to intensive induction therapy once or in a sequential dosing schedule. Glasdegib, the small-molecule inhibitor of smoothened (SMO), also showed improved overall survival in patients not eligible for intensive chemotherapy when combined with low-dose cytarabine compared to low-dose cytarabine alone. These findings warrant further investigations in the phase III GnG trial. |
|---|
| DOI: | doi:10.1186/s13063-021-05703-w |
|---|
| URL: | kostenfrei: Volltext: https://doi.org/10.1186/s13063-021-05703-w |
|---|
| | DOI: https://doi.org/10.1186/s13063-021-05703-w |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | acute myeloid leukemia |
|---|
| | gemtuzumab ozogamicin |
|---|
| | glasdegib |
|---|
| | measurable residual disease |
|---|
| K10plus-PPN: | 1782338373 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
| |
|
|---|
| | |
|---|
| Lokale URL UB: |  Zum Volltext |
|---|
Rationale and design of the 2 by 2 factorial design GnG-trial / Jaramillo Segura, Sonia [VerfasserIn]; 03 November 2021 (Online-Ressource)
